ENTA

SEC source: 0001062993-22-007005 · form4.xml · derivative · entry 1

Hata Yujiro S · CIK 0001649119 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2032-03-03

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 3, 2022), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2023 annual meeting of stockholders.

SEC source: 0001062993-22-007003 · form4.xml · derivative · entry 1

FOLETTA MARK G · CIK 0001236389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2032-03-03

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 3, 2022), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2023 annual meeting of stockholders.

SEC source: 0001062993-22-007001 · form4.xml · derivative · entry 1

CARTER BRUCE L A · CIK 0001225503 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2032-03-03

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 3, 2022), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2023 annual meeting of stockholders.

SEC source: 0001062993-22-006708 · form4.xml · derivative · entry 7

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,481 shares

Expires 2025-06-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-22-006708 · form4.xml · nonDerivative · entry 5

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,982

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.28, inclusive.

SEC source: 0001062993-22-006708 · form4.xml · nonDerivative · entry 4

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,463

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-006708 · form4.xml · derivative · entry 6

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,481

Underlying: Common Stock · 24,339 shares

Expires 2025-06-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-22-006708 · form4.xml · nonDerivative · entry 3

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,982

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021.

SEC source: 0001062993-22-006708 · form4.xml · nonDerivative · entry 2

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,082

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.97, inclusive.

SEC source: 0001062993-22-006708 · form4.xml · nonDerivative · entry 1

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,321

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-004520 · form4.xml · nonDerivative · entry 3

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,864

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001062993-22-004520 · form4.xml · nonDerivative · entry 2

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,416

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 20, 2019 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-22-004520 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,127

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 20, 2019 that vested as a result of the achievement of a research and development milestone in calendar 2021 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-22-004522 · form4.xml · nonDerivative · entry 3

Luu Brendan · CIK 0001842369 · Sr. VP, Business Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,723

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001062993-22-004522 · form4.xml · nonDerivative · entry 2

Luu Brendan · CIK 0001842369 · Sr. VP, Business Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,212

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 20, 2019 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-22-004522 · form4.xml · nonDerivative · entry 1

Luu Brendan · CIK 0001842369 · Sr. VP, Business Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,086

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 20, 2019 that vested as a result of the achievement of a research and development milestone in calendar 2021 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-22-004518 · form4.xml · nonDerivative · entry 3

Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,239

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001062993-22-004518 · form4.xml · nonDerivative · entry 2

Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,196

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 20, 2019 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-22-004518 · form4.xml · nonDerivative · entry 1

Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,777

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 20, 2019 that vested as a result of the achievement of a research and development milestone in calendar 2021 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-22-004514 · form4.xml · nonDerivative · entry 3

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 339,242

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001062993-22-004514 · form4.xml · nonDerivative · entry 2

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 340,195

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 20, 2019 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-22-004514 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 337,776

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 20, 2019 that vested as a result of the achievement of a research and development milestone in calendar 2021 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-22-004516 · form4.xml · nonDerivative · entry 3

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,982

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001062993-22-004516 · form4.xml · nonDerivative · entry 2

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,936

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 20, 2019 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-22-004516 · form4.xml · nonDerivative · entry 1

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,517

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 20, 2019 that vested as a result of the achievement of a research and development milestone in calendar 2021 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-22-004512 · form4.xml · nonDerivative · entry 3

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,078

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001062993-22-004512 · form4.xml · nonDerivative · entry 2

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,036

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 20, 2019 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-22-004512 · form4.xml · nonDerivative · entry 1

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,617

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 20, 2019 that vested as a result of the achievement of a research and development milestone in calendar 2021 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-22-004510 · form4.xml · nonDerivative · entry 3

Luly Jay R. · CIK 0001571211 · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 716,464

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001062993-22-004510 · form4.xml · nonDerivative · entry 2

Luly Jay R. · CIK 0001571211 · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 718,819

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 20, 2019 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-22-004510 · form4.xml · nonDerivative · entry 1

Luly Jay R. · CIK 0001571211 · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 712,418

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 20, 2019 that vested as a result of the achievement of a research and development milestone in calendar 2021 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-22-001104 · form4.xml · derivative · entry 2

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,063 shares

Expires 2022-06-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-22-001104 · form4.xml · nonDerivative · entry 1

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 710,791

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-001041 · form4.xml · derivative · entry 5

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,664

Underlying: Common Stock · 3,336 shares

Expires 2026-11-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-22-001041 · form4.xml · derivative · entry 4

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,820

Underlying: Common Stock · 9,200 shares

Expires 2025-06-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-22-001041 · form4.xml · nonDerivative · entry 3

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,902

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.90, inclusive.

SEC source: 0001062993-22-001041 · form4.xml · nonDerivative · entry 2

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,438

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-001041 · form4.xml · nonDerivative · entry 1

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,102

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-21-012216 · form4.xml · nonDerivative · entry 1

Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,226

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 20, 2020.

SEC source: 0001062993-21-012213 · form4.xml · derivative · entry 12

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,180

Underlying: Common Stock · 4,773 shares

Expires 2027-11-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-21-012213 · form4.xml · derivative · entry 11

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,020

Underlying: Common Stock · 8,750 shares

Expires 2025-06-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 10

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,902

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.

F9 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.25, inclusive.

SEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 9

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,103

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.

F8 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $89.02 to $89.88, inclusive.

SEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 8

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,002

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.

F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $88.01 to $88.90, inclusive.

SEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 7

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,902

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.

F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $87.23 to $87.92, inclusive.

SEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 6

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,402

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.

F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.03 to $86.91, inclusive.

SEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 5

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,102

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $85.04 to $85.98, inclusive.

SEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 4

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,838

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.43 to $84.98, inclusive.

SEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 3

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,425

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 2

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,652

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.